Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of restricted stock units (RSUs) to eight newly-hired employees. The compensation committee approved a total of 57,000 shares of BioCryst common stock as inducement awards on July 1, 2025.
The RSUs will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. These grants were made under Nasdaq Listing Rule 5635(c)(4) and are subject to BioCryst's Inducement Equity Incentive Plan terms.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has agreed to sell its European ORLADEYO® business to Neopharmed Gentili for up to $264 million, comprising a $250 million upfront payment and up to $14 million in future milestones.
The company plans to use the proceeds to retire its remaining $249 million term debt from Pharmakon, eliminating approximately $70 million in future interest payments. BioCryst expects to end 2027 with approximately $700 million in cash and no term debt, representing a $400 million increase from prior guidance.
The transaction, expected to close by early October, includes the transfer of BioCryst's European organization to Neopharmed Gentili, resulting in projected annual operating expense savings of at least $50 million for BioCryst.
BioCryst Pharmaceuticals (NASDAQ: BCRX) has announced its participation in two major upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 4:55 p.m. ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025, at 8:40 a.m. ET. Investors can access live audio webcasts and replays of both presentations through the Investors & Media section of BioCryst's website.